A new therapy offers hopeful perspectives for patients suffering from spondyloarthropathy
Spondyloarthropathies are rheumatic infectious diseases affecting the spinal column and peripheral joints and tendons. These diseases either occur as such (Bechterew`s disease or ankylosing spondylitis), or are combined with skin psoriasis, inflammatory intestinal diseases (Crohn`s disease and ulcerating colitis), and eye infection (uveitis).
These diseases effect about 1% of total world population and often develop into seriously debilitating conditions with complete stiffening of the spinal column and destruction of the peripheral joints (hips, knees, wrists and/or fingers). Thus far, treatment of these diseases has been limited to the administration of non-steroid anti-inflammatory drugs, which may have a benevolent effect on the subjective complaints of pain, but does not effect the evolution of the disease.
Tumor Necrosis Factor is a small molecule (a cytokine) which is released by the disposal cells (macrophages) of the immune systems at sites where the inflammation occurs and which, in case of spondyloarthropathy, induces changes in the bone, joints and tendons.
Two years ago the Department of Rheumatology of the University of Ghent, Belgium, initiated an open study involving the treatment of 21 patients suffering from various forms of these diseases with intravenous injections of a monoclonal antibody targeting the Tumor Nacrosis Factor (Infliximab). The results were impressive not only with regard to the complaints, but also with regard to the symptoms of infection of the spinal column and the peripheral sites, and the infection factors measured in the blood. These results were confirmed in a double blind study involving 40 other patients, the data that were published in the March 6, 2002 issue of Arthritis and Rheumatology, the leading scientific journal in the area of rheumatology.
The conclusion of the study can be summarized as follows. The authors report the successful results of a double-blind placebo-controlled study with Infliximab on several sub-types of spondyloarthropathies. For the first time, we have an effective therapeutic option for severe cases. Long-term results (more than 1 year) of patients treated in the initial open study were already disclosed in a previous publication. The future of patients suffering from spondyloarthropathy is hopeful. It seems as if all requirements have been met to allow us to hope that this treatment will be able to prevent the stiffening of the spinal column and the destruction of the peripheral joints, and that the quality of life of these patients will improve considerably.
Eric VEYS | alphagalileo
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...